Promising Shionogi Candidate Moves Ahead In Gram-Negative Pneumonia
Novel Shionogi antibiotic candidate set to move ahead following positive results in Gram-negative pneumonia, where resistance and unmet needs remain critical factors.
You may also be interested in...
The 11-member GNA NOW alliance aims to move a treatment for some of the most threatening drug-resistant bacteria through early-phase development by 2024 using a mix of public and private funds.
The latest drug development news and highlights for our US FDA Performance Tracker.
Headquartered in both China and US, the new firm will help partners bring drugs to China and other Asian markets. Novavax licenses COVID-19 vaccine in Japan to Takeda, following previous week’s deal for the vaccine in India.